[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Acidic tumor microenvironment,CD98,pH-dependent,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"F. Yang<sup>1<\/sup>, L. Wang<sup>2<\/sup>, X. Tian<sup>3<\/sup>, X. Qiu<sup>2<\/sup>, J. Chen<sup>1<\/sup>, W. Qi<sup>2<\/sup>, g. Li<sup>1<\/sup>, H. Liu<sup>2<\/sup>, J. Liu<sup>1<\/sup>, S. Huang<sup>2<\/sup>, <b>B. Ye<\/b><sup>1<\/sup>, Q. Wu<sup>2<\/sup>, B. Zhao<sup>2<\/sup>, W. Li<sup>3<\/sup>, J. Sui<sup>1<\/sup>, Z. Chen<sup>2<\/sup>; <br\/><sup>1<\/sup>Huahui Health, Ltd., Beijing, China, <sup>2<\/sup>ProfoundBio (Suzhou) Co., Ltd., Suzhou, China, <sup>3<\/sup>National Institute of Biological Sciences, Beijing, Beijing, China","CSlideId":"","ControlKey":"47665c15-0ded-4ec7-977c-ad759f817fa1","ControlNumber":"10581","DisclosureBlock":"&nbsp;<b>F. Yang, <\/b> None..<br><b>L. Wang, <\/b> None..<br><b>X. Tian, <\/b> None..<br><b>X. Qiu, <\/b> None..<br><b>J. Chen, <\/b> None..<br><b>W. Qi, <\/b> None..<br><b>G. Li, <\/b> None..<br><b>H. Liu, <\/b> None..<br><b>J. Liu, <\/b> None..<br><b>S. Huang, <\/b> None..<br><b>B. Ye, <\/b> None..<br><b>Q. Wu, <\/b> None.&nbsp;<br><b>B. Zhao, <\/b> <br><b>ProfoundBio<\/b> Employment. <br><b>W. Li, <\/b> <br><b>Huahuihealth Ltd.<\/b> Other, Co-founder.<br><b>J. Sui, <\/b> None..<br><b>Z. Chen, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10475","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB425","PresenterBiography":null,"PresenterDisplayName":"Bin Ye, PhD","PresenterKey":"9ab397cb-e4fd-4747-99d3-b3f41a2d1be9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB425. A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"IDO1,Tumor microenvironment,Hippo pathway,Immune checkpoint,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"H. He, N. Kim, S. Han, <b>Z. Chu<\/b>; <br\/>Crossignal Therapeutics, Inc, La Jolla, CA","CSlideId":"","ControlKey":"649adf26-d72c-4fb8-88f3-fd13399681a0","ControlNumber":"10789","DisclosureBlock":"<b>&nbsp;H. He, <\/b> <br><b>Crossignal Therapeutics<\/b> Employment. <br><b>N. Kim, <\/b> <br><b>Crossignal Therapeutics<\/b> Employment. <br><b>S. Han, <\/b> <br><b>Crossignal Therpeutics<\/b> Employment. <br><b>Z. Chu, <\/b> <br><b>Crossignal Therapeutics, Inc<\/b> Employment.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10476","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB426","PresenterBiography":null,"PresenterDisplayName":"Zhi-Liang (Zak) Chu, PhD","PresenterKey":"994ff553-196c-4e44-9bb2-3bd4e91b5d82","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB426. Evidence for a role of GPR35 in IDO1-mediated tumor immune escape by regulating Hippo-YAP pathway","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Evidence for a role of GPR35 in IDO1-mediated tumor immune escape by regulating Hippo-YAP pathway","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"Combination therapy,Ubiquitination,Homologous recombination,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Awasthi<sup>1<\/sup>, D. J. McGrail<sup>2<\/sup>, S. Yi<sup>3<\/sup>, <b>N. Sahni<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>UT MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Cleveland Clinic, Cleveland, OH, <sup>3<\/sup>University of Texas at Austin, Austin, TX","CSlideId":"","ControlKey":"2cc07285-2655-41ea-9df6-b57177e2ac01","ControlNumber":"10943","DisclosureBlock":"&nbsp;<b>S. Awasthi, <\/b> None..<br><b>D. J. McGrail, <\/b> None..<br><b>S. Yi, <\/b> None..<br><b>N. Sahni, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10477","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB427","PresenterBiography":null,"PresenterDisplayName":"Nidhi Sahni, PhD","PresenterKey":"cd48e276-3758-4515-9954-77ca005f56ee","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB427. UBA1 blockade induces homologous recombination deficiency and is synthetic lethal with PARP inhibition","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"UBA1 blockade induces homologous recombination deficiency and is synthetic lethal with PARP inhibition","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"Cancer therapy,Targeted therapy,Small molecule inhibitor,TEAD\/YAP,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K. Zhao<\/b>, Y. Zhag, Y. Shi, J. Chen; <br\/>Kygent Therapeutics, Shanghai, China","CSlideId":"","ControlKey":"2e814751-6888-473e-a296-ca06d27fc4c9","ControlNumber":"10504","DisclosureBlock":"&nbsp;<b>K. Zhao, <\/b> None..<br><b>Y. Zhag, <\/b> None..<br><b>Y. Shi, <\/b> None..<br><b>J. Chen, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10478","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB428","PresenterBiography":null,"PresenterDisplayName":"Kehao Zhao, PhD","PresenterKey":"8612c6d2-70b9-412c-a042-24dd1e970bbc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB428. Discovery of KY-001:A Direct Inhibitor of TEAD-YAP Protein-Protein Interaction for the Treatment of Advanced Solid Tumors with Abnormal Hippo Signaling Pathway","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of KY-001:A Direct Inhibitor of TEAD-YAP Protein-Protein Interaction for the Treatment of Advanced Solid Tumors with Abnormal Hippo Signaling Pathway","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"Cancer-associated fibroblasts,Novel anticancer agents,In situ hybridization,Drug-discovery screen,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. Sarnecky<sup>1<\/sup>, J. Lewis<sup>2<\/sup>, J. Allen<sup>2<\/sup>, D. Davies<sup>2<\/sup>, M. Metzger<sup>1<\/sup>, B. Thomas<sup>2<\/sup>, C. Rohlff<sup>3<\/sup>, <b>B. Cairns<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Oxford BioTherapeutics Inc, San Jose, CA, <sup>2<\/sup>Oxford BioTherapeutics Ltd, Oxford, United Kingdom, <sup>3<\/sup>Oxford BioTherapeutics Inc, Oxford, United Kingdom","CSlideId":"","ControlKey":"6b8e67b3-c80e-4dd8-827f-47f671ededb1","ControlNumber":"10781","DisclosureBlock":"&nbsp;<b>J. Sarnecky, <\/b> None..<br><b>J. Lewis, <\/b> None..<br><b>J. Allen, <\/b> None..<br><b>D. Davies, <\/b> None..<br><b>M. Metzger, <\/b> None..<br><b>B. Thomas, <\/b> None..<br><b>C. Rohlff, <\/b> None..<br><b>B. Cairns, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10479","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB429","PresenterBiography":null,"PresenterDisplayName":"Belinda Cairns, D Phil","PresenterKey":"6be910a5-237e-46ca-bf3b-9f1f278e1b97","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB429. Discovery and identification of a novel cancer associated fibroblast target using Oxford Biotherapeutics (OBTs) OGAP discovery platform","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery and identification of a novel cancer associated fibroblast target using Oxford Biotherapeutics (OBTs) OGAP discovery platform","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"Breast cancer,Tumor suppressor gene,G-quadruplex ,Small molecule drugs,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Razzaq<\/b><sup>1<\/sup>, S. Ravichandran<sup>2<\/sup>, N. Parveen<sup>1<\/sup>, K. Kim<sup>1<\/sup>; <br\/><sup>1<\/sup>Sungkyunkwan University, School of Medicine, Suwon-si, Korea, Republic of, <sup>2<\/sup>Stanford University, Department of Biology, Stanford, CA","CSlideId":"","ControlKey":"200a080b-a694-45b6-b296-f33eca83b737","ControlNumber":"9760","DisclosureBlock":"&nbsp;<b>M. Razzaq, <\/b> None..<br><b>S. Ravichandran, <\/b> None..<br><b>N. Parveen, <\/b> None..<br><b>K. Kim, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10480","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB430","PresenterBiography":null,"PresenterDisplayName":"Maria Razzaq, MS","PresenterKey":"f75ceb30-6339-4b30-b32a-3b448b459635","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB430. Identification of therapeutic target in breast cancer using G-quadruplex binding ligands","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identification of therapeutic target in breast cancer using G-quadruplex binding ligands","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"Cancer therapy,Drug discovery,Focal adhesion kinase (FAK),Therapeutic target,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. Reyes<\/b>, R. Khatiwala, T. Marlowe; <br\/>University of Arizona, Phoenix, AZ","CSlideId":"","ControlKey":"aa9f42de-6cc0-4791-9b38-05fb5dedd4b3","ControlNumber":"10846","DisclosureBlock":"&nbsp;<b>L. Reyes, <\/b> None..<br><b>R. Khatiwala, <\/b> None..<br><b>T. Marlowe, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10481","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB431","PresenterBiography":null,"PresenterDisplayName":"Lauren Reyes","PresenterKey":"0b71cfb9-9f3f-4e20-bad8-b1719ff0163c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB431. Direct comparison of focal adhesion kinase (FAK) therapeutic modalities in cancer: Kinase, FAT, and PROTAC","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Direct comparison of focal adhesion kinase (FAK) therapeutic modalities in cancer: Kinase, FAT, and PROTAC","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"Target discovery,Glioblastoma multiforme,Aptamer,Proteomics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>X. Wei<\/b>, M. An, R. Santhanam, B. Richardson, L. Vu, J. Saul, A. Walton, M. Gee, D. Martin, A. Hubbard, A. Rodin, M. Rosenow, T. Hornung; <br\/>Caris Life Sciences, Inc., Phoenix, AZ","CSlideId":"","ControlKey":"b23a635c-8da0-4e4e-af66-58eec65cd5a8","ControlNumber":"10852","DisclosureBlock":"&nbsp;<b>X. Wei, <\/b> None..<br><b>M. An, <\/b> None..<br><b>R. Santhanam, <\/b> None..<br><b>B. Richardson, <\/b> None..<br><b>L. Vu, <\/b> None..<br><b>J. Saul, <\/b> None..<br><b>A. Walton, <\/b> None..<br><b>M. Gee, <\/b> None..<br><b>D. Martin, <\/b> None..<br><b>A. Hubbard, <\/b> None..<br><b>A. Rodin, <\/b> None..<br><b>M. Rosenow, <\/b> None..<br><b>T. Hornung, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10482","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB432","PresenterBiography":null,"PresenterDisplayName":"Xixi Wei, PhD","PresenterKey":"1c4df278-112e-4a88-9aeb-be7aff7b6b18","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB432. Identification of novel drug targets using the ADAPT biotargeting system on FFPE tissue from patients with glioblastoma multiforme","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identification of novel drug targets using the ADAPT biotargeting system on FFPE tissue from patients with glioblastoma multiforme","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-05 New targets,,"},{"Key":"Keywords","Value":"Breast cancer,Metastasis,Proteasome-mediated degradation,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K. M. Lin<\/b>, X. Li, L. Kotula; <br\/>SUNY Upstate Medical University, Syracuse, NY","CSlideId":"","ControlKey":"bdbf40cf-66cb-4c42-a735-2358403b9a14","ControlNumber":"10793","DisclosureBlock":"&nbsp;<b>K. M. Lin, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>L. Kotula, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10483","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB433","PresenterBiography":null,"PresenterDisplayName":"Kevin Lin, BS","PresenterKey":"1e80bbc8-aec7-475e-87a8-d4b523f5fba0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB433. Targeting of ABI1 via DNA-based PROTACs","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting of ABI1 via DNA-based PROTACs","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-06 Novel assay technology,,"},{"Key":"Keywords","Value":"Organoids,Circulating tumor cells,Drug assay,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"W.-H. Kuo<sup>1<\/sup>, Y.-J. Huang<sup>2<\/sup>, J.-Y. Chen<sup>2<\/sup>, Y.-C. Wu<sup>3<\/sup>, C.-C. Chen<sup>4<\/sup>, M. D. Pegram<sup>5<\/sup>, <b>Y.-C. Chang<\/b><sup>2<\/sup>; <br\/><sup>1<\/sup>College of Medicine, National Taiwan University, Taipei, Taiwan, <sup>2<\/sup>AcroCyte Therapeutics Inc., New Taipei City, Taiwan, <sup>3<\/sup>Institute of Molecular and Cellular Biology, National Taiwan University, Taipei, Taiwan, <sup>4<\/sup>Department of Chemistry, National Taiwan Normal University, Taipei, Taiwan, <sup>5<\/sup>Stanford Cancer Institute, Stanford University, Stanford, CA","CSlideId":"","ControlKey":"c6e56641-958c-48ef-b4c4-0c1c18fd2a23","ControlNumber":"10601","DisclosureBlock":"&nbsp;<b>W. Kuo, <\/b> None.&nbsp;<br><b>Y. Huang, <\/b> <br><b>AcroCyte Therapeutics Inc.<\/b> Employment. <br><b>J. Chen, <\/b> <br><b>AcroCyte Therapeutics Inc.<\/b> Employment.<br><b>Y. Wu, <\/b> None..<br><b>C. Chen, <\/b> None..<br><b>M. D. Pegram, <\/b> None.&nbsp;<br><b>Y. Chang, <\/b> <br><b>AcroCyte Therapeutics Inc.<\/b> Employment.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10484","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB434","PresenterBiography":null,"PresenterDisplayName":"Ying-Chih Chang, PhD","PresenterKey":"da941739-ffc6-453a-b522-d777e8c4c35d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB434. Rapid and reproducible expansion of rare tumor cells: The R<sup>3<\/sup>CE platform for personalized medicine","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Rapid and reproducible expansion of rare tumor cells: The R<sup>3<\/sup>CE platform for personalized medicine","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-06 Novel assay technology,,"},{"Key":"Keywords","Value":"Preclinical testing,Organoids,Biomarkers,Drug discovery,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"L. Xue<sup>1<\/sup>, L. Wijler<sup>2<\/sup>, M. Hornsveld<sup>2<\/sup>, S. Guo<sup>1<\/sup>, L. Price<sup>2<\/sup>, <b>M. Putker<\/b><sup>2<\/sup>, L. Bourre<sup>3<\/sup>; <br\/><sup>1<\/sup>Crown Bioscience, Suzhou, China, <sup>2<\/sup>Crown Bioscience Netherlands B.V., Leiden, Netherlands, <sup>3<\/sup>Crown Bioscience Inc, San Diego, CA","CSlideId":"","ControlKey":"ba36966d-7cd2-4a6b-8fef-2b4100f0a17b","ControlNumber":"10774","DisclosureBlock":"&nbsp;<b>L. Xue, <\/b> None..<br><b>L. Wijler, <\/b> None..<br><b>M. Hornsveld, <\/b> None..<br><b>S. Guo, <\/b> None..<br><b>L. Price, <\/b> None..<br><b>M. Putker, <\/b> None..<br><b>L. Bourre, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10485","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB435","PresenterBiography":null,"PresenterDisplayName":"Marrit Putker, PhD","PresenterKey":"25544074-a08b-47e7-97f1-149df9c82590","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB435. Large panel organoid drug testing combined with biomarker analysis: Unveiling prospects for mechanism of action identification and preclinical patient stratification","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Large panel organoid drug testing combined with biomarker analysis: Unveiling prospects for mechanism of action identification and preclinical patient stratification","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-06 Novel assay technology,,"},{"Key":"Keywords","Value":"Fluorescence,Target Occupancy,Liquid Biopsies,Drug Dosing,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>F. Becker<\/b>; <br\/>Intana Bioscience GmbH, Planegg, Germany","CSlideId":"","ControlKey":"c4d3e2f0-d835-4aab-9a1d-6c9f648075fc","ControlNumber":"9599","DisclosureBlock":"<b>&nbsp;F. Becker, <\/b> <br><b>Intana Bioscience GmbH<\/b> Employment, Other Business Ownership. <br><b>siTOOLs Biotech GmbH<\/b> Other Business Ownership. <br><b>Varolis GmbH<\/b> Other Business Ownership. <br><b>Alpine Antiviral GmbH<\/b> Other Business Ownership.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10486","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB436","PresenterBiography":null,"PresenterDisplayName":"Frank Becker, PhD","PresenterKey":"7a74625b-ef20-4108-883e-470c37e488f8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB436. Using FCCS to monitor target occupancy in cells and patient biopsies","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Using FCCS to monitor target occupancy in cells and patient biopsies","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-06 Novel assay technology,,"},{"Key":"Keywords","Value":"Bladder cancer,Invasion,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"D. Ewell, N. Vue, S. Moinuddin, T. Sarkar, F. Ahsan, <b>R. L. Vinall<\/b>; <br\/>California Northstate University, College of Pharmacy, Elk Grove, CA","CSlideId":"","ControlKey":"8b1b2cd3-5dad-44e1-8e3d-2029d99141fc","ControlNumber":"10785","DisclosureBlock":"&nbsp;<b>D. Ewell, <\/b> None..<br><b>N. Vue, <\/b> None..<br><b>S. Moinuddin, <\/b> None..<br><b>T. Sarkar, <\/b> None..<br><b>F. Ahsan, <\/b> None..<br><b>R. L. Vinall, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10487","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB437","PresenterBiography":null,"PresenterDisplayName":"Ruth Vinall, MS;PhD","PresenterKey":"476b16b3-0c21-462d-8395-6d4a2d0d147f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB437. Development of a bladder cancer-on-a-chip assay to assess the invasive potential of bladder cancer cells","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Development of a bladder cancer-on-a-chip assay to assess the invasive potential of bladder cancer cells","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-07 Novel drug delivery systems,,"},{"Key":"Keywords","Value":"Cytokines,Nanoparticle,Drug delivery,Immunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Q. Su, S. Gutowski, A. Burcham, B. Allu, Z. Chen, F. Stavros, R. Han, <b>J. B. Miller<\/b>, T. Zhao; <br\/>OncoNano Medicine, Southlake, TX","CSlideId":"","ControlKey":"acc4125f-77ed-4291-8593-e1cd98d0b47d","ControlNumber":"9710","DisclosureBlock":"<b>&nbsp;Q. Su, <\/b> <br><b>OncoNano Medicine, Inc.<\/b> Employment, Stock Option. <br><b>S. Gutowski, <\/b> <br><b>OncoNano Medicine, Inc.<\/b> Employment, Stock Option. <br><b>A. Burcham, <\/b> <br><b>OncoNano Medicine, Inc.<\/b> Employment, Stock Option. <br><b>B. Allu, <\/b> <br><b>OncoNano Medicine, Inc.<\/b> Employment, Stock Option. <br><b>Z. Chen, <\/b> <br><b>OncoNano Medicine, Inc.<\/b> Employment, Stock Option. <br><b>F. Stavros, <\/b> <br><b>OncoNano Medicine, Inc.<\/b> Employment, Stock Option. <br><b>R. Han, <\/b> <br><b>OncoNano Medicine, Inc.<\/b> Employment, Stock Option. <br><b>J. B. Miller, <\/b> <br><b>OncoNano Medicine<\/b> Employment, Stock Option. <br><b>T. Zhao, <\/b> <br><b>OncoNano Medicine, Inc.<\/b> Employment, Stock Option.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10488","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB438","PresenterBiography":null,"PresenterDisplayName":"Jason Miller, PhD","PresenterKey":"5801146f-8f50-47a0-a7af-b00d4071cdbb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB438. Preclinical characterization of ONM-412, an ultra-pH sensitive nanoparticle encapsulated IL-12 fusion protein","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preclinical characterization of ONM-412, an ultra-pH sensitive nanoparticle encapsulated IL-12 fusion protein","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-07 Novel drug delivery systems,,"},{"Key":"Keywords","Value":"DNA damage response,Drug delivery,Pharmacokinetics,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. A. Hangasky<\/b><sup>1<\/sup>, J. Henise<sup>1<\/sup>, D. Charych<sup>2<\/sup>, C. W. Carreras<sup>1<\/sup>, G. Ashley<sup>1<\/sup>, D. V. Santi<sup>1<\/sup>; <br\/><sup>1<\/sup>ProLynx LLC, San Francisco, CA, <sup>2<\/sup>ShynianBio Inc., San Francisco, CA","CSlideId":"","ControlKey":"25257586-f9b2-4103-a3e0-0f8ff7d72442","ControlNumber":"10464","DisclosureBlock":"<b>&nbsp;J. A. Hangasky, <\/b> <br><b>ProLynx LLC<\/b> Employment, Stock Option. <br><b>J. Henise, <\/b> <br><b>ProLynx Inc<\/b> Employment, Stock Option. <br><b>D. Charych, <\/b> <br><b>ShynianBio Inc.<\/b> Employment, Stock Option. <br><b>C. W. Carreras, <\/b> <br><b>ProLynx<\/b> Employment, Stock Option. <br><b>G. Ashley, <\/b> <br><b>ProLynx Inc<\/b> Employment, Stock Option, Patent. <br><b>D. V. Santi, <\/b> <br><b>ProLynx Inc<\/b> Employment, Stock Option, Patent.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10489","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB439","PresenterBiography":null,"PresenterDisplayName":"John Hangasky","PresenterKey":"034debc7-9e92-4df0-8597-dce654b801c8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB439. Intra-tumoral administration of releasable hydrogel microsphere drug conjugates for long acting therapeutics","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Intra-tumoral administration of releasable hydrogel microsphere drug conjugates for long acting therapeutics","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-07 Novel drug delivery systems,,"},{"Key":"Keywords","Value":"Drug delivery,Nanoparticle,In vivo,Cisplatin,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Goldberg<\/b><sup>1<\/sup>, A. Manzi<sup>1<\/sup>, S. Cantin<sup>1<\/sup>, P. Conway<sup>1<\/sup>, J. Shikora<sup>1<\/sup>, A. McFarland<sup>1<\/sup>, M. Cayer<sup>1<\/sup>, L. Dunn<sup>1<\/sup>, C. Ball<sup>1<\/sup>, A. T. Pearson<sup>2<\/sup>, A. J. Rosenberg<sup>2<\/sup>, N. Agrawal<sup>2<\/sup>, E. Izumchenko<sup>2<\/sup>; <br\/><sup>1<\/sup>Privo Technologies, Peabody, MA, <sup>2<\/sup>University of Chicago, Chicago, IL","CSlideId":"","ControlKey":"d583d239-c2b1-4ebd-94ae-0c86a1fa4f33","ControlNumber":"10513","DisclosureBlock":"&nbsp;<b>M. Goldberg, <\/b> None..<br><b>A. Manzi, <\/b> None..<br><b>S. Cantin, <\/b> None..<br><b>P. Conway, <\/b> None..<br><b>J. Shikora, <\/b> None..<br><b>A. McFarland, <\/b> None..<br><b>M. Cayer, <\/b> None..<br><b>L. Dunn, <\/b> None..<br><b>C. Ball, <\/b> None..<br><b>A. T. Pearson, <\/b> None..<br><b>A. J. Rosenberg, <\/b> None..<br><b>N. Agrawal, <\/b> None..<br><b>E. Izumchenko, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10490","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB440","PresenterBiography":null,"PresenterDisplayName":"MANIJEH GOLDBERG, PhD, MBA, MS, MS, BS","PresenterKey":"c18dac18-3a03-41fd-abbe-12b4b8329e64","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB440. PRV131 is an effective and safe polymeric nanoparticle suspension for intratumoral cisplatin delivery","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"PRV131 is an effective and safe polymeric nanoparticle suspension for intratumoral cisplatin delivery","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-08 Targeting the tumor microenvironment in drug development,,"},{"Key":"Keywords","Value":"Oncolytic virus,Liver metastasis,Systemic administration,Anti-tumor efficacy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. Kim<\/b><sup>1<\/sup>, Y. Yang<sup>1<\/sup>, S. Won<sup>1<\/sup>, N. Lee<sup>2<\/sup>, S. Lee<sup>2<\/sup>, M.-J. Park<sup>2<\/sup>, B.-J. Jung<sup>2<\/sup>, Y.-K. Hong<sup>2<\/sup>, H.-R. Kim<sup>1<\/sup>, D.-S. Lee<sup>1<\/sup>, K. Oh<sup>2<\/sup>; <br\/><sup>1<\/sup>Seoul National University, College of Medicine, Seoul, Korea, Republic of, <sup>2<\/sup>SillaJen, Inc., Yongin, Korea, Republic of","CSlideId":"","ControlKey":"d7ad126b-51a1-4f5e-b3c6-6a4d6b18278e","ControlNumber":"9909","DisclosureBlock":"&nbsp;<b>E. Kim, <\/b> None..<br><b>Y. Yang, <\/b> None..<br><b>S. Won, <\/b> None..<br><b>N. Lee, <\/b> None..<br><b>S. Lee, <\/b> None..<br><b>M. Park, <\/b> None..<br><b>B. Jung, <\/b> None..<br><b>Y. Hong, <\/b> None..<br><b>H. Kim, <\/b> None..<br><b>D. Lee, <\/b> None..<br><b>K. Oh, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10491","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB441","PresenterBiography":null,"PresenterDisplayName":"Eunhye Kim","PresenterKey":"83412cd6-84c1-42af-9048-1b3073e10129","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB441. An intravenous compatible oncolytic vaccinia virus treated hepatic metastasis of colon cancer through extensive cancer cell killing and activation of cytotoxic effector differentiation<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"An intravenous compatible oncolytic vaccinia virus treated hepatic metastasis of colon cancer through extensive cancer cell killing and activation of cytotoxic effector differentiation<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-08 Targeting the tumor microenvironment in drug development,,"},{"Key":"Keywords","Value":"T cell engager,Antitumor activity,Antibody,HLA,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Fabian Scheifele<\/b><sup>1<\/sup>, Stephanie Jungmichel<sup>1<\/sup>, Nagjie Alijaj<sup>1<\/sup>, Athanasia Dasargyri<sup>1<\/sup>, Romina Doerig<sup>1<\/sup>, Philip Knobel<sup>1<\/sup>, Hannes Merten<sup>1<\/sup>, Philipp Richle<sup>1<\/sup>, Thomas Schleier<sup>1<\/sup>, Anna Sobieraj<sup>1<\/sup>, Alessio Vantellini<sup>1<\/sup>, Tim Fugmann<sup>2<\/sup>, Rom Leidner<sup>3<\/sup>, Swethajit Biswas<sup>1<\/sup>, Leonardo Borras<sup>1<\/sup><br><br\/><sup>1<\/sup>CDR-Life Inc., Horgen, Switzerland,<sup>2<\/sup>Alithea Bio UG, Freiburg, Germany,<sup>3<\/sup>Providence Cancer Institute, Portland, OR","CSlideId":"","ControlKey":"1b9ce3d0-7b12-4136-a78b-75885f0d8411","ControlNumber":"9913","DisclosureBlock":"&nbsp;<b>F. Scheifele, <\/b> None..<br><b>S. Jungmichel, <\/b> None..<br><b>N. Alijaj, <\/b> None..<br><b>A. Dasargyri, <\/b> None..<br><b>R. Doerig, <\/b> None..<br><b>P. Knobel, <\/b> None..<br><b>H. Merten, <\/b> None..<br><b>P. Richle, <\/b> None..<br><b>T. Schleier, <\/b> None..<br><b>A. Sobieraj, <\/b> None..<br><b>A. Vantellini, <\/b> None..<br><b>T. Fugmann, <\/b> None.&nbsp;<br><b>R. Leidner, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Travel. <br><b>Incyte<\/b> Grant\/Contract, Data Safety Monitoring Board. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Merck<\/b> Advisory. <br><b>Vir<\/b> Advisory. <br><b>CDR-Life<\/b> Advisory.<br><b>S. Biswas, <\/b> None..<br><b>L. Borras, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10492","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB442","PresenterBiography":null,"PresenterDisplayName":"Fabian Scheifele","PresenterKey":"46a07708-b976-48e2-ab81-0b63e0ca73a5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB442. Novel antibodies against a KK-LC-1-derived peptide presented on HLA-A*01 on tumor cells","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Novel antibodies against a KK-LC-1-derived peptide presented on HLA-A*01 on tumor cells","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-08 Targeting the tumor microenvironment in drug development,,"},{"Key":"Keywords","Value":"Glioblastoma,Small molecule inhibitor,Tumor microenvironment,Drug discovery,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H. Vankayalapati<\/b>, C. Lin, Z. Li, K. Medley, D. J. Bearss; <br\/>Biolexis Therapeutics Inc., American Fork, UT","CSlideId":"","ControlKey":"9eea03a0-8c34-47cd-9135-d17b3a2c7e3e","ControlNumber":"10855","DisclosureBlock":"<b>&nbsp;H. Vankayalapati, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>Signalexis<\/b> Employment, Stock Option. <br><b>Arrien Pharmaceuticals<\/b> Stock Option. <br><b>C. Lin, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Employment. <br><b>Z. Li, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Employment. <br><b>K. Medley, <\/b> <br><b>Biolexis Therapeutics, Inc<\/b> Employment, Stock Option. <br><b>D. J. Bearss, <\/b> <br><b>Biolexis Therapeutics, Inc.<\/b> Stock Option. <br><b>Signalexis<\/b> Stock Option. <br><b>Halia Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>University of Utah<\/b> Scientific Advisor.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10494","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB444","PresenterBiography":null,"PresenterDisplayName":"Hariprasad Vankayalapati, PhD","PresenterKey":"a78cb8e4-78ad-46a5-a8e9-444c45f798ef","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB444. Identification of a novel and selective Transglutaminase 2 (TGM2) inhibitors modulate tumor microenvironment in Glioblastoma","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identification of a novel and selective Transglutaminase 2 (TGM2) inhibitors modulate tumor microenvironment in Glioblastoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-08 Targeting the tumor microenvironment in drug development,,"},{"Key":"Keywords","Value":"PD-1,Ubiquitination,T cell,Tumor microenvironment,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"H.-C. Hsieh<sup>1<\/sup>, J.-J. Hung<sup>2<\/sup>, <b>Y.-C. Wang<\/b><sup>3<\/sup>; <br\/><sup>1<\/sup>National Cheng-Kung University, College of Medicine, Institute of Basic Medical Sciences, Tainan, Taiwan, <sup>2<\/sup>National Cheng-Kung University, Department of Biotechnology and Bioindustry Sciences, Tainan, Taiwan, <sup>3<\/sup>National Cheng-Kung University, College of Medicine, Department of Pharmacology, Tainan, Taiwan","CSlideId":"","ControlKey":"1e114f99-ddce-4cf8-83fb-5a5523ac2fd9","ControlNumber":"9756","DisclosureBlock":"&nbsp;<b>H. Hsieh, <\/b> None..<br><b>J. Hung, <\/b> None..<br><b>Y. Wang, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10495","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB445","PresenterBiography":null,"PresenterDisplayName":"Yi-Ching Wang, PhD","PresenterKey":"ef884d15-f245-4df2-b733-f2f463035c44","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB445. USP24 suppresses T cell anti-tumor activity by enhancing the stability of the PD-1 protein","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"USP24 suppresses T cell anti-tumor activity by enhancing the stability of the PD-1 protein","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-08 Targeting the tumor microenvironment in drug development,,"},{"Key":"Keywords","Value":"Tumor microenvironment,Metastasis,Cancer therapy,Cancer-associated fibroblasts,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"B. Prieto, M. Nez, V. I. Cerdfa, <b>J. Cerda-Infante<\/b>; <br\/>Environ, Santiago, Chile","CSlideId":"","ControlKey":"5aec1873-bb8c-450b-b435-eca0633ac90e","ControlNumber":"10882","DisclosureBlock":"&nbsp;<b>B. Prieto, <\/b> None..<br><b>M. Nez, <\/b> None..<br><b>V. I. Cerdfa, <\/b> None..<br><b>J. Cerda-Infante, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10496","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB446","PresenterBiography":null,"PresenterDisplayName":"Javier Cerda-Infante, MS;PhD","PresenterKey":"7b6e44ca-2826-4894-b238-45508e5b0497","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB446. &#8203;Decoding the mechanism of metastasis: A novel CAF-therapy that blocks the tumor microenvironment and reverses metastatic traits in all solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"&#8203;Decoding the mechanism of metastasis: A novel CAF-therapy that blocks the tumor microenvironment and reverses metastatic traits in all solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-08 Targeting the tumor microenvironment in drug development,,"},{"Key":"Keywords","Value":"Microfluidics,Microenvironment,Angiogenesis,Lymphangiogenesis,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D.-H. Kim<\/b>; <br\/>Sungshin Women's Univ., Gangbuk-gu, Korea, Republic of","CSlideId":"","ControlKey":"6678b5c7-d74e-47cb-9191-47fd8b79aea6","ControlNumber":"10544","DisclosureBlock":"&nbsp;<b>D. Kim, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10497","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"22","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB447","PresenterBiography":null,"PresenterDisplayName":"Da-Hyun Kim, PhD;VMD","PresenterKey":"26f339c5-9f40-45b5-9035-1454d152c675","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB447. Drug delivery and efficacy testing using vascularized tumor-on-a-chip","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Drug delivery and efficacy testing using vascularized tumor-on-a-chip","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-09 Other,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Bispecific ADC,Trop-2,Nectin4,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"W. Wang, J. Li, <b>L. Guan<\/b>, M. Xu, Q. Yin; <br\/>VelaVigo (Shanghai) Limited, Shanghai, China","CSlideId":"","ControlKey":"7ce214ac-0b69-4864-80fa-d78e6a45afaf","ControlNumber":"9777","DisclosureBlock":"&nbsp;<b>W. Wang, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>L. Guan, <\/b> None..<br><b>M. Xu, <\/b> None..<br><b>Q. Yin, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10498","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"23","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB448","PresenterBiography":null,"PresenterDisplayName":"Jing Li, MBA;MD;PhD","PresenterKey":"3139fcf7-9ab7-405f-ab48-357fd6038942","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB448. VBC103: An innovative Trop2\/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"VBC103: An innovative Trop2\/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-01 Drug resistance in molecular targeted therapies,,"},{"Key":"Keywords","Value":"Breast cancer,Drug resistance,PIK3CA,Kinase inhibitors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>F. Fece de la Cruz<\/b><sup>1<\/sup>, A. Varkaris<sup>1<\/sup>, E. E. Martin<sup>2<\/sup>, B. L. Norden<sup>1<\/sup>, N. Chevalier<sup>1<\/sup>, A. M. Kehlmann<sup>1<\/sup>, I. Leshchiner<sup>3<\/sup>, H. Barnes<sup>1<\/sup>, S. Ehnstrom<sup>1<\/sup>, P. Patel<sup>1<\/sup>, J. S. Kim<sup>1<\/sup>, H. Ellis<sup>1<\/sup>, I. Sanidas<sup>1<\/sup>, K. T. Lau<sup>1<\/sup>, A. Bardia<sup>1<\/sup>, L. M. Spring<sup>1<\/sup>, S. J. Isakoff<sup>1<\/sup>, J. K. Lennerz<sup>1<\/sup>, G. Getz<sup>1<\/sup>, R. B. Corcoran<sup>1<\/sup>, D. Juric<sup>1<\/sup>; <br\/><sup>1<\/sup>Massachusetts General Hospital Cancer Center, Boston, MA, <sup>2<\/sup>Broad Institute of MIT and Harvard, Cambridge, MA, <sup>3<\/sup>Department of Medicine, Boston University, Boston, MA","CSlideId":"","ControlKey":"e71c97b5-fb09-4fae-8292-9cca969f5262","ControlNumber":"10810","DisclosureBlock":"&nbsp;<b>F. Fece de la Cruz, <\/b> None..<br><b>A. Varkaris, <\/b> None..<br><b>E. E. Martin, <\/b> None..<br><b>B. L. Norden, <\/b> None..<br><b>N. Chevalier, <\/b> None..<br><b>A. M. Kehlmann, <\/b> None..<br><b>I. Leshchiner, <\/b> None..<br><b>H. Barnes, <\/b> None..<br><b>S. Ehnstrom, <\/b> None..<br><b>P. Patel, <\/b> None..<br><b>J. S. Kim, <\/b> None..<br><b>H. Ellis, <\/b> None..<br><b>I. Sanidas, <\/b> None..<br><b>K. T. Lau, <\/b> None..<br><b>A. Bardia, <\/b> None..<br><b>L. M. Spring, <\/b> None..<br><b>S. J. Isakoff, <\/b> None..<br><b>J. K. Lennerz, <\/b> None..<br><b>G. Getz, <\/b> None..<br><b>R. B. Corcoran, <\/b> None..<br><b>D. Juric, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10499","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"24","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB449","PresenterBiography":null,"PresenterDisplayName":"Ferran Fece de la Cruz, PhD","PresenterKey":"ac7ae9f2-ee14-453e-b317-9561394b9800","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB449. Strategies to overcome resistance to PI3Kalpha-selective inhibitors mediated by acquired alterations in the PI3K\/AKT pathway","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Strategies to overcome resistance to PI3Kalpha-selective inhibitors mediated by acquired alterations in the PI3K\/AKT pathway","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-01 Drug resistance in molecular targeted therapies,,"},{"Key":"Keywords","Value":"Targeted therapy,Capivasertib,Drug resistance,Patient derived organoids (PDO),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Mearns<\/b><sup>1<\/sup>, A. Pearson<sup>1<\/sup>, L.-X. Sim<sup>1<\/sup>, R. Cutts<sup>1<\/sup>, P. Sritharan<sup>1<\/sup>, H. Shah<sup>1<\/sup>, A. Gulati<sup>1<\/sup>, S. Williamson<sup>2<\/sup>, S. Barry<sup>2<\/sup>, E. De-Bruin<sup>2<\/sup>, N. C. Turner<sup>1<\/sup>; <br\/><sup>1<\/sup>The Institute of Cancer Research, London, London, United Kingdom, <sup>2<\/sup>AstraZeneca, Cambridge, United Kingdom","CSlideId":"","ControlKey":"96c52888-2e06-4a82-a372-98cbd4a78eca","ControlNumber":"9531","DisclosureBlock":"<b>&nbsp;S. Mearns, <\/b> <br><b>MRC (Medical Research Council)<\/b> Grant\/Contract, PhD studentship funding (iCASE scheme). <br><b>AstraZeneca<\/b> Grant\/Contract, PhD studentship funding (iCASE scheme).<br><b>A. Pearson, <\/b> None..<br><b>L. Sim, <\/b> None..<br><b>R. Cutts, <\/b> None..<br><b>P. Sritharan, <\/b> None..<br><b>H. Shah, <\/b> None..<br><b>A. Gulati, <\/b> None.&nbsp;<br><b>S. Williamson, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>S. Barry, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>E. De-Bruin, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>N. C. Turner, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Advisory board honoraria and research funding. <br><b>BioRad<\/b> Grant\/Contract, Research funding. <br><b>Bristol-Myers Squibb<\/b> Other, Advisory board honoraria. <br><b>Lilly<\/b> Other, Advisory board honoraria. <br><b>Merck Sharpe and Dohme<\/b> Grant\/Contract, Other, Advisory board honoraria and research funding. <br><b>Novartis<\/b> Other, Advisory board honoraria. <br><b>Pfizer<\/b> Grant\/Contract, Other, Advisory board honoraria and research funding. <br><b>Roche \/ Genentech<\/b> Grant\/Contract, Other, Advisory board honoraria and research funding. <br><b>GlaxoSmithKline<\/b> Other, Advisory board honoraria. <br><b>Guardant Health<\/b> Grant\/Contract, Research funding. <br><b>Zentalis pharmaceuticals<\/b> Other, Advisory board honoraria. <br><b>Repare 44 therapeutics<\/b> Other, Advisory board honoraria. <br><b>Arvinas<\/b> Other, Advisory board honoraria. <br><b>Inivata<\/b> Grant\/Contract, Other, Advisory board honoraria and research funding. <br><b>Invitae<\/b> Grant\/Contract, Research funding. <br><b>Personalis<\/b> Grant\/Contract, Research funding. <br><b>Natera<\/b> Grant\/Contract, Research funding.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10500","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"25","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB450","PresenterBiography":null,"PresenterDisplayName":"Sarah Mearns, BS","PresenterKey":"dc3ba612-f6ca-47ca-9f11-75c6e97c7db2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB450. Mechanisms of acquired resistance to AKT inhibitor capivasertib in AKT1 mutant patient derived breast cancer models","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Mechanisms of acquired resistance to AKT inhibitor capivasertib in AKT1 mutant patient derived breast cancer models","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-01 Drug resistance in molecular targeted therapies,,"},{"Key":"Keywords","Value":"Epigenetics,Transcription factor,Drug resistance,Targeted therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Chatterjee<\/b><sup>1<\/sup>, V. Olivas<sup>1<\/sup>, W. Wu<sup>1<\/sup>, T. Tang<sup>2<\/sup>, B. Powell<sup>3<\/sup>, T. Bivona<sup>1<\/sup>; <br\/><sup>1<\/sup>UCSF - University of California San Francisco, San Francisco, CA, <sup>2<\/sup>Vivace Therapeutics, San Francisco, CA, <sup>3<\/sup>Kinnate Biopharma, San Francisco, CA","CSlideId":"","ControlKey":"6ba22abd-e7d4-4b7b-b3e1-267aa97f7b10","ControlNumber":"9763","DisclosureBlock":"&nbsp;<b>N. Chatterjee, <\/b> None..<br><b>V. Olivas, <\/b> None..<br><b>W. Wu, <\/b> None..<br><b>T. Tang, <\/b> None..<br><b>B. Powell, <\/b> None..<br><b>T. Bivona, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10501","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"26","PosterboardNumber":"27","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB451","PresenterBiography":null,"PresenterDisplayName":"Nilanjana Chatterjee, PhD","PresenterKey":"e21d7151-bebb-466b-8571-f687fb5b1d5d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB451. Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-01 Drug resistance in molecular targeted therapies,,"},{"Key":"Keywords","Value":"Malignant melanoma,CD133,Akt,Stem cells,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"C. M. Simbulan-Rosenthal<sup>1<\/sup>, <b>N. Islam<\/b><sup>1<\/sup>, R. Alobaidi<sup>1<\/sup>, A. Moreno<sup>1<\/sup>, V. Patil<sup>1<\/sup>, A. Alzharani<sup>1<\/sup>, P. Sykora<sup>2<\/sup>, D. S. Rosenthal<sup>1<\/sup>; <br\/><sup>1<\/sup>Georgetown Univ. School of Medicine, Washington, DC, <sup>2<\/sup>Amelia Technologies, LLC, Washington, DC","CSlideId":"","ControlKey":"f2080d38-aa60-42e9-aa51-f67ef29748f3","ControlNumber":"10568","DisclosureBlock":"&nbsp;<b>C. M. Simbulan-Rosenthal, <\/b> None..<br><b>N. Islam, <\/b> None..<br><b>R. Alobaidi, <\/b> None..<br><b>A. Moreno, <\/b> None..<br><b>V. Patil, <\/b> None..<br><b>A. Alzharani, <\/b> None.&nbsp;<br><b>P. Sykora, <\/b> <br><b>Amelia Technologies, LLC<\/b> Employment.<br><b>D. S. Rosenthal, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10502","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"27","PosterboardNumber":"28","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB452","PresenterBiography":null,"PresenterDisplayName":"Nusrat Islam, MS","PresenterKey":"e0179d92-5c65-46bc-a54d-54b6ed382acd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB452. Effects of AKT1, 2, and 3 knock-out by CRISPR-Cas9 in CD133+human melanoma stem cells treated with MEK and AKT inhibitors","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Effects of AKT1, 2, and 3 knock-out by CRISPR-Cas9 in CD133+human melanoma stem cells treated with MEK and AKT inhibitors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-01 Drug resistance in molecular targeted therapies,,"},{"Key":"Keywords","Value":"Tyrosine kinase inhibitor,EGFR TKI resistance,Tyrosine kinase,NSCLC,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. C. Gunder<\/b><sup>1<\/sup>, I. Pulido<sup>1<\/sup>, J. H. Becker<sup>2<\/sup>, M. G. Massad<sup>1<\/sup>, T. Shimamura<sup>1<\/sup>; <br\/><sup>1<\/sup>University of Illinois at Chicago, Chicago, IL, <sup>2<\/sup>Northwestern University, Chicago, IL","CSlideId":"","ControlKey":"dfde5ef0-9eb9-477a-8be7-d90225adbad3","ControlNumber":"10851","DisclosureBlock":"&nbsp;<b>L. C. Gunder, <\/b> None..<br><b>I. Pulido, <\/b> None..<br><b>J. H. Becker, <\/b> None..<br><b>M. G. Massad, <\/b> None..<br><b>T. Shimamura, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10503","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"28","PosterboardNumber":"29","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB453","PresenterBiography":null,"PresenterDisplayName":"Laura Gunder","PresenterKey":"7daf1804-04f6-42a0-a82e-ae4efab53bdf","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB453. Distinct mechanism of CXCR7 activation in EGFR-mutated NSCLC by chemokines","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"598","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 4","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Distinct mechanism of CXCR7 activation in EGFR-mutated NSCLC by chemokines","Topics":null,"cSlideId":""}]